MS
ACAD icon

Maven Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

Maven Securities’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-38,998
Closed -$1.42M – 351
2019
Q3 		$1.42M Buy
+38,998
New +$1.18M 0.45% 62

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Maven Securities's ACAD Position: Q4 2019 in Review

Maven Securities sold out of Acadia Pharmaceuticals (ACAD) in Q4 2019, closing a stake of 38,998 shares — an estimated $1.42M sold.

Maven Securities first reported a position in ACAD in Q3 2019 and held it in 1 quarter. The position peaked at $1.42M in Q3 2019. 273 funds tracked by Wall St. Rank hold ACAD as of Q4 2019.

  • Maven Securities reported no remaining Acadia Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Maven Securities sold 38,998 Acadia Pharmaceuticals shares in Q4 2019, an estimated $1.42M.
  • Maven Securities first reported a position in Acadia Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Maven Securities's Acadia Pharmaceuticals position peaked at $1.42M in Q3 2019.
  • 273 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2019.

Based on Maven Securities's 13F filing for Q4 2019, filed 14 Feb 2020.